European Journal of Clinical Microbiology and Infectious Diseases

, Volume 8, Issue 10, pp 878–887

Impact of the dosage schedule on the efficacy of ceftazidime, gentamicin and ciprofloxacin inKlebsiella pneumoniae pneumonia and septicemia in leukopenic rats

  • R. Roosendaal
  • I. A. J. Bakker-Woudenberg
  • M. van den Berghe-van Raffe
  • J. C. Vink-van den Berg
  • M. F. Michel
Article

DOI: 10.1007/BF01963774

Cite this article as:
Roosendaal, R., Bakker-Woudenberg, I.A.J., van den Berghe-van Raffe, M. et al. Eur. J. Clin. Microbiol. Infect. Dis. (1989) 8: 878. doi:10.1007/BF01963774

Abstract

The impact of the dosage schedule on the therapeutic efficacy of antibiotics was investigated in experimentalKlebsiella pneumoniae pneumonia and septicemia in leukopenic rats. The daily doses (mg/kg) that protected 50 % of the animals from death, when calculated for administration at 6 h intervals or by continuous infusion, were as follows: ceftazidime 24.4 and 1.5 (p<0.001), gentamicin 2.8 and 3.8 (p>0.05), and ciprofloxacin 3.3 and 6.5 (p<0.05), respectively. This correlates with the observation that ceftazidime killedKlebsiella pneumoniae slowly but constantly, and relatively independently of concentration, whereas killing by gentamicin or ciprofloxacin was rapid, and markedly dependent on antibiotic concentration. Exposure of bacteria for 1 h to concentrations of fivefold the MBC did not give rise to a postantibiotic effect for any of the drugs. In our model ceftazidime was far more effective when given continuously than when administered at 6 h intervals. On the other hand, the activity of gentamicin was not influenced by the mode of administration, whereas ciprofloxacin was slightly more effective when given intermittently. However, to avoid misleading conclusions regarding the use of antibiotics in humans, the pharmacokinetic differences between rats and man must be considered when interpreting these results.

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1989

Authors and Affiliations

  • R. Roosendaal
    • 1
  • I. A. J. Bakker-Woudenberg
    • 1
  • M. van den Berghe-van Raffe
    • 1
  • J. C. Vink-van den Berg
    • 1
  • M. F. Michel
    • 1
  1. 1.Department of Clinical Microbiology and Antimicrobial TherapyErasmus University RotterdamRotterdamThe Netherlands